AIKIDO PHARMA INC (AIKI) Stock Price, Forecast & Analysis
USA - NASDAQ:AIKI - US0088753043 - Common Stock
AIKI Key Statistics, Chart & Performance
The current stock price of AIKI is 3.56 USD. In the past month the price decreased by -10.1%. In the past year, price decreased by -67.28%.
AIKI Latest News, Press Relases and Analysis
AIKI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About AIKI
Company Profile
AIkido Pharma, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The Company’s pipeline consists of patented technology from universities and researchers. The firm advances its therapeutic drug pipeline through a collaboration with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. Its pancreatic drug candidate, DHA-dFdC, developed at and licensed from the University of Texas at Austin, is a chemotherapy treatment for advanced pancreatic cancer.
Company Info
AIKIDO PHARMA INC
One Rockefeller Plaza, 11Th Floor
New York City NEW YORK 10020 US
CEO: Anthony Hayes
Employees: 4
Phone: 13473217646.0
AIKIDO PHARMA INC / AIKI FAQ
What does AIKI do?
AIkido Pharma, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The Company’s pipeline consists of patented technology from universities and researchers. The firm advances its therapeutic drug pipeline through a collaboration with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. Its pancreatic drug candidate, DHA-dFdC, developed at and licensed from the University of Texas at Austin, is a chemotherapy treatment for advanced pancreatic cancer.
What is the stock price of AIKIDO PHARMA INC today?
The current stock price of AIKI is 3.56 USD. The price increased by 0.28% in the last trading session.
What is the dividend status of AIKIDO PHARMA INC?
AIKI does not pay a dividend.
What is the ChartMill rating of AIKIDO PHARMA INC stock?
AIKI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for AIKI stock?
AIKIDO PHARMA INC (AIKI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.37).
AIKI Technical Analysis
AIKI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AIKI. AIKI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
AIKI Financial Highlights
Over the last trailing twelve months AIKI reported a non-GAAP Earnings per Share(EPS) of -3.37. The EPS decreased by -879.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
AIKI Forecast & Estimates
7 analysts have analysed AIKI and the average price target is 16.32 USD. This implies a price increase of 358.43% is expected in the next year compared to the current price of 3.56.